SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)
ACAD 25.44+2.3%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche3/18/2005 2:57:53 PM
  Read Replies (2) of 588
 
10-K is out. Does anybody remember notice that BOTH Allergan molecules have advanced to phase I (neuropathic pain)??

Drug Program

--------------------------------------------------------------------------------
    Stage of Development

--------------------------------------------------------------------------------
    Commercialization Rights

--------------------------------------------------------------------------------
 
ACP-103 for treatment-induced dysfunctions in Parkinson’s disease
    Phase II    ACADIA 
ACP-103 as an adjunctive therapy for schizophrenia
    Phase II    ACADIA 
ACP-104 for schizophrenia
    Phase II    ACADIA 
AGN-XX and AGN-YY for neuropathic pain
    Phase I    Allergan 
AC-262271 for glaucoma
    Preclinical development    Allergan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News